NewLimit vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrated restoration of youthful killing function in aged human CD8 T cells.
About
NewLimit is a longevity biotechnology company that demonstrated the first-ever restoration of youthful killing function in aged human CD8 T cells using transcription factor payloads — a major biological milestone with implications for cancer immunotherapy and immune aging. The company raised $130 million in Series B financing led by Kleiner Perkins, followed by $45 million in additional financing from Eli Lilly at a $1.62 billion valuation, with clinical studies in planning.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.